Shubhra Ray, MD
Pulmonary Disease · York, PANPI 1245278175
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 92.9% of it on its own, with 6 other manufacturers making up the rest.
Across 67 payments — averaging $62.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Galvanize Therapeutics, Inc$75
- Pinnacle Biologics, Inc$61
- Olympus America Inc.$59
- Edwards Lifesciences$39
- Johnson & Johnson$38
- plus $24 from 1 others
What the payments were for
- Travel & lodging$2,22853%
- Food & beverage$1,94046%
- Education$241%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 61 | $3,896 |
| Galvanize Therapeutics, Inc | 1 | $75 |
| Pinnacle Biologics, Inc | 1 | $61 |
| Olympus America Inc. | 1 | $59 |
| Edwards Lifesciences | 1 | $39 |
| Johnson & Johnson | 1 | $38 |
| CSL Behring | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,503
How this compares
$4,193 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 103 | $77,199 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $37,181 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $24,772 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,617 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,063 |
| Montelukast Sodium | 20 | $341 |
| Fluticasone Propionate | 14 | $175 |
| Prednisone | 17 | $35 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in York
- Rumon ChakravartyYork$22K
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.